FEROZSONS LABORATORIES LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 222.5 PKR | -1.57% |
|
-1.29% | +0.86% |
Valuation
| Fiscal Period: Juni | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Capitalization 1 | 12,781 | 5,949 | 9,674 | - |
| Enterprise Value (EV) 1 | 12,781 | 5,949 | 9,674 | 9,674 |
| P/E ratio | 30.7 x | 21.9 x | 8.46 x | 6.23 x |
| Yield | - | - | 1.75% | 2.38% |
| Capitalization / Revenue | - | 0.52 x | 0.49 x | 0.42 x |
| EV / Revenue | - | 0.52 x | 0.49 x | 0.42 x |
| EV / EBITDA | - | - | - | - |
| EV / FCF | - | - | - | - |
| FCF Yield | - | - | - | - |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 43,469 | 43,469 | 43,469 | - |
| Reference price 2 | 294.0 | 136.8 | 222.5 | 222.5 |
| Announcement Date | 8/31/21 | 10/7/23 | - | - |
1PKR in Million2PKR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Juni | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net sales 1 | - | 11,457 | 19,615 | 23,001 |
| EBITDA | - | - | - | - |
| EBIT | - | 1,001 | - | - |
| Operating Margin | - | 8.73% | - | - |
| Earnings before Tax (EBT) | - | - | - | - |
| Net income | 1,173 | 271.3 | - | - |
| Net margin | - | 2.37% | - | - |
| EPS 2 | 9.592 | 6.240 | 26.30 | 35.70 |
| Free Cash Flow | - | - | - | - |
| FCF margin | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - |
| Dividend per Share 2 | - | - | 3.900 | 5.300 |
| Announcement Date | 8/31/21 | 10/7/23 | - | - |
1PKR in Million2PKR
Estimates
Balance Sheet Analysis
| Fiscal Period: June | 2021 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Debt | - | - | - | - |
| Net Cash position | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - |
| Free Cash Flow | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - |
| Assets | - | - | - | - |
| Book Value Per Share | - | - | - | - |
| Cash Flow per Share | - | - | - | - |
| Capex | - | - | - | - |
| Capex / Sales | - | - | - | - |
| Announcement Date | 8/31/21 | 10/7/23 | - | - |
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
222.5
PKR
Average target price
325
PKR
Spread / Average Target
+46.04%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +0.86% | 34.74M | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- FEROZ Stock
- Financials Ferozsons Laboratories Limited
